Dilated cardiomyopathy (DCM) is a complex disease with multiple causes and various
pathogenic mechanisms. Despite improvements in the prognosis of patients with DCM in the …

In the last years, major progress has occurred in heart failure (HF) management. The 2023
ESC focused update of the 2021 HF guidelines introduced new key recommendations …

Background A diagnosis of Lamin proteins A and C cardiomyopathy (LMNA-CM) not only
impacts disease prognosis, but also leads to specific guideline-recommended treatment …

To solve the clinical transformation dilemma of lamin A/C (LMNA)-mutated dilated
cardiomyopathy (LMD), we developed an LMNA-mutated primate model based on the …

Aims LMNA‐related dilated cardiomyopathy (DCM) is a rare disease with an incompletely
defined phenotype. The phase 3 REALM‐DCM trial evaluated a potential disease‐modifying …

Abstract Purpose of the Review The definition of arrhythmogenic cardiomyopathy (ACM) has
expanded beyond desmosomal arrhythmogenic right ventricular cardiomyopathy (ARVC) to …

Purpose of review This review aims to explore how a diagnosis of LMNA-related
cardiomyopathy (LMNA-CM) informs clinical management, focusing on the prevention and …

Cardiomyopathy is a group of disease characterized by structural and functional damage to
the myocardium. The etiologies of cardiomyopathies are diverse, spanning from genetic …

More than 500 000 cardiovascular implantable electronic devices (CIEDs) are implanted in
the European Society of Cardiology countries each year. The role of cardiovascular imaging …

Introduction: LMNA splicing mutations occur in 9.1% of cases with cardiac involvement
cases, but the phenotype and severity of disease they cause have not yet been …